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Abstract
Oxidative stress is due to an imbalance of antioxidant/pro-oxidant homeostasis and is associated with the progression of
several neurological diseases, including Parkinson’s and Alzheimer’s disease and amyotrophic lateral sclerosis. Furthermore,
oxidative stress is responsible for the neuronal loss and dysfunction associated with disease pathogenesis. Survivin is a
member of the inhibitors of the apoptosis (IAP) family of proteins, but its neuroprotective effects have not been studied.
Here, we demonstrate that SurR9-C84A, a survivin mutant, has neuroprotective effects against H2O2-induced neurotoxicity.
Our results show that H2O2 toxicity is associated with an increase in cell death, mitochondrial membrane depolarisation, and
the expression of cyclin D1 and caspases 9 and 3. In addition, pre-treatment with SurR9-C84A reduces cell death by
decreasing both the level of mitochondrial depolarisation and the expression of cyclin D1 and caspases 9 and 3. We further
show that SurR9-C84A increases the antioxidant activity of GSH-peroxidase and catalase, and effectively counteracts oxidant
activity following exposure to H2O2. These results suggest for the first time that SurR9-C84A is a promising treatment to
protect neuronal cells against H2O2-induced neurotoxicity.
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Introduction
Parkinson’s disease (PD) is a chronic and progressive neurode-
generative disorder, in which dopaminergic (DArgic) neurons in the
substantia nigra are selectively degenerated. This degeneration
leads to the formation of fibrillar cytoplasmic inclusions known as
Lewy bodies (LBs) [1]. Oxidative stress is a critical factor in this
disease, as shown by different studies including direct analysis of
postmortem samples and indirect demonstrations of oxidative stress
capacity in inducing nigral cell loss [2,3]. Oxidative stress results
from insufficient scavenging of reactive oxygen species and is
reported to be the cause of the selective degeneration of DArgic
neurons in PD through both mitochondrial dysfunction and
apoptosis [4]. Oxidative stress occurs in DArgic neurons due to
the metabolism of dopamine, which generates various molecules
such as hydrogen peroxide, superoxide radicals and dopamine-
quinone that act as endogenous toxins [5].
Although the exact mechanism underlying the degeneration of
DArgic neurons in PD is not currently clear, mitochondrial
dysfunction, genetic mutations, protein aggregation, and ultimate-
ly apoptosis are the major contributing factors that have been
identified so far [6].
There is an increasing interest in using inhibitors of apoptosis
(IAP) family proteins to target different aspects of degenerative
diseases. Reportedly, adenoviral delivery of NAIP, HIAP1 and
HIAP2 has shown protective effects on ischemic damage [7] and
sciatic axotomy [8]. Moreover, the BH4 domain of Bcl-x attached
to TAT, a membrane transport peptide, has a neuroprotective
effect against acute hypoxia/ischemia injury [9]. Using wild type
IAP family proteins in human trials always raises concerns due to
their role in cancer formation [10,11,12] and in the induction of
mitosis in postmitotic neurons. Alternatively, developing IAP
mutants capable of protecting neurons will provide insight into the
treatment of degenerative diseases of the brain.
Survivin is a unique member of the IAP family and has an
intriguing function in the chromosomal passenger complex (CPC).
It contributes to microtubule instability and is necessary for both
the correct alignment of chromosomes on mitotic spindles and
biorientation (the capture of sister kinetochores by microtubules
from opposite spindle poles) prior to anaphase [13]. Survivin has a
dominant role in the inhibition of apoptosis through dimerisation
with its co-factors XIAP and hepatitis B X-interacting protein
(HBXIP) [14,15]. Although these unique features make survivin an
ideal target for neuroprotection and proliferation, no efforts have
been made to study its subcellular network during neurodegen-
erative diseases and its potential use as a target for neuroprotec-
tion. Previously we found the SurR9-C84A has neuroprotective
effect against the post differentiation retinoic acid induce cell death
and cytotixic effect of activated T-cells supernatant [16,17].
In the present study, we demonstrate that pre-treatment with
SurR9-C84A can protect the differentiated DArgic such as
neuroblastoma SK-N-SH cells against H2O2-induced oxidative
damage in terms of intracellular redox and cellular death. Here,
we demonstrate that pre-treatment with SurR9-C84A can protect
differentiated DArgic cells such as neuroblastoma SK-N-SH cells
against H2O2-induced oxidative damage in terms of intracellular
redox and cell death. We also report the ability of survivin to
activate antioxidant scavengers, including GSH-peroxidase
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e15865(GSHPx), GSH-reductase (GSHR), GSH-transferase (GST),
superoxide dismutase (SOD), and catalase (CAT).
Materials and Methods
Cell line and culture conditions
Human SK-N-SH, obtained from the American Type Culture
Collection (ATCC) were grown as a monolayer in the Dulbecco’s
Minimum Essential Medium (DMEM) media supplemented with
10% of heat-inactivated Foetal Bovine Serum (FBS), penicillin (20
units/ml) and streptomycin (20 mg/ml) at 37uC in a saturated
humid atmosphere with 5% CO2. As the cells became confluent,
they were split after treatment with Trypsin-EDTA.
To determine cell viability and mitochondrial depolarization SK-
N-SH cells were differentiated in 96 well plate at 10
4 cells per well.
For TUNEL assay SK-N-SH cells were seeded in BD Falcon
TM 8-
well culture slides (surface area 0.7 cm
2/well) at 10
4 cells/well. To
evaluate GSH enzyme activities cells were seeded in 6 well plates
(surface area 2.2 cm
2/well). To initiate the differentiation in SK-N-
SH, cells were grown in the DMEM media containing the 20 mM
retinoic acid (RA) (Sigma-Aldrich) under the dark conditions with
replacement of the conditioned media every 48–72 hr for two
weeks. Cells were considered to be differentiated if they had at least
one process longer than the cell body regarded as neurite [18].
Before any treatment, the differentiation media were replaced
with DMEM media. All experiments were performed after 24 hr
of incubation at 37uCi n5 %C O 2. In order to evaluate the effect of
SurR9-C84A on viability, differentiated SK-N-SH cells were
treated with different concentration of SurR9-C84A (10–100 mg/
ml) for 24 hr. Similarly, cells were treated with different
concentration of H2O2 (10–500 mM) for 24 hr. The 75 mg/ml
concentration of SurR9-C84A had the best effect on viability and
300 mM concentration of H2O2 had the significant cytotoxic
effect, and therefore were selected to study the neuroprotective
effect of SurR9-C84A. All the SurR9-C84A incubation was 24 hr
a head of H2O2 therapy. As a control, ascorbic acid was used with
the same treatment condition of SurR9-C84A therapy.
Construction of BIR motif mutant of Survivin expressing
vector and protein purification
Construction, purification and internalization of dominant-negative
cell-permeable (9 arginine residues) form of survivin mutant (SurR9-
C84A) have been fully explained in our previous works [19,20].
Cell viability assay
To evaluate the level of cell toxicity, MTT assay was conducted.
The colorimetric MTT (3-(4, 5-dimethylthiazol-2yl)-2, 5-diphenyl-
tetrazoliumbromide)assaywasconductedwithdifferentiatedSK-N-
SH cells. Differentiated cells were pre-treated with/without 75 mg/
ml of SurR9-C84A or ascorbic acid for 24 hr followed by treatment
with300 mMH 2O2 for24 hrpriorto MTTassay. Each experiment
was conducted in triplicate wells. Mean (6SEM) values were
calculated from at least three independent experiments.
Lactate Dehydrogenase (LDH) Release Assay
Apoptotic and necrotic cells release LDH in the media. Difference in
the LDH concentration was measured using cytotoxicity detection kit
(Roche). Briefly, differentiated cells were pre-treated for 24 hr with
50 mg/ml SurR9-C84A, 50 mg/ml ascorbic acid and then treated with
300 mMH 2O2f o r3h r .F o ra n a l y s i s ,1 0 0ml supernatant was extracted
from each well and placed in separate 96-well plate. The 100 ml
catalyst solution was added to each well and incubated at 37uCf o r
30 min. Absorbance was measured at 490 nm using a microplate
reader. Total cellular LDH was determined using total cell lysate
following 2% triton X-100. The assay medium served as a low control
and its absorbance was subtracted from all absorbance measurement to
estimate the cytotoxicity (%) as:
ODtest{ODlow control
ODhigh control{ODlow control
|100%:
Western blotting
For western blot analysis, 70 mg of differentiated cell lysate protein
was used. Cell lysate was prepared using the RIPA buffer (150 mM
sodium chloride, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1%
SDS and 50 mM Tris, PH 8.0) containing protease inhibitor tablets
(Roche Applied Science). The total protein content was measured
using the Bradford assay. Samples were electrophoresed and
transferred to the PVDF membrane. Primary antibodies used were
goat anti-b-actin (1/1000, Santa Cruz) and mouse anti-cyclin D1 (1/
2000, Cell signalling). Secondary antibodies were peroxidase
conjugate anti-mouse (1/2000, Cell signalling), peroxidase conjugate
anti-goat (1/10000, sigma Aldrich). The blots were developed using
ECL system (Amersham Biosciences, Arlington Heights, IL, USA).
Determination of caspase 9 and 3 activities
Caspase enzyme activity was determined as reported previously.
Briefly treated differentiated cells were washed with PBS and
cell lysate was prepared using the lysis buffer (150 mM
sodium chloride, 1 mM ethylene diamine tetraacetate (EDTA),
1 mM ethylene glycol-bis(2-aminoethyl)-N,N,N’,N’-tetraacetic ac-
id (EGTA), 1% Triton X-100) containing protease inhibitor tablets
(Roche Applied Science). Caspase activity was measured using the
cell signaling PathScanH Sandwich ELISA techniques following
the supplier instruction. The resulting absorbance was read at
490 nm on an ELISA plate reader (Ansys, Expert plus).
Determination of the intrinsic Mitochondrial Membrane
Potential (Dym)
Mitochondrial membrane potential variation was determined
using the MitoLight Mitochondrial Apoptosis Detection Kit
(Chemicon) according to the manufacturer’s instruction. Mito-
Light is a lipophilic cationic dye, which stains living cell
mitochondria according to their membrane potentials. In healthy
cells, the dye accumulates and aggregates in the mitochondria and
fluoresces red (Em=5852590 nm) while in apoptotic cells, the
dye remains in the cytosol and fluorescence green
(Em=5272530 nm).
Briefly, cells were washed with PBS. Diluted mitolight reagent
was added to the cells and incubated at 37uCi n5 %C O 2 for
20 min. Cells were washed with PBS and the fluorescent were
measured at lexcitation=485 nm and lemission=580 nm with a
spectrofluorometer. The ratio of red (Em=585–590 nm) to green
(Em=527–530 nm) reflects the Dym.
TUNEL staining
TUNEL (terminal deoxynucleotidyl transferasemediated
dUTP-biotin nick end-labeling) staining performed using In Situ
Cell Death Detection Kit (Roche) following the maufacturer’s
instruction. Slides were mounted with mounting media (Vector
Labs, USA).
Preparation of cell lysate for determination of enzyme
activity
Differentiated SK-N-SH cells were washed three times with cold
PBS.Cellsweresubsequently scraped and collected in1 mL ofPBS.
The pallet was lysed by sonication and centrifuged for 15 min at
10000 g at4uC.Thesupernatant wereusedforthedeterminationof
enzyme activity analyses after protein concentration determination.
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GST activity was determined using the Glutathione S-
Transferase Assay Kit (Cayman) according to the manufacturer’s
instruction. Briefly, GST activity was spectrophotometrically
assessed by measuring the conjugation of 1-chloro-2, 4-dinitro-
benzene (CDNB) with glutathione at 340 nm. GSHR activity was
assessed using the Glutathione Reductase Assay Kit (Cayman)
following the manufacturer’s instruction and expressed as nmol
of NADPH oxidation per min/mg of total cellular protein per
assay.
GSHPx, SOD and CAT activities were determined using the
GSHPx, SOD and CAT determination Kits (Cayman), respec-
tively, according to the manufacturer’s instructions. GSHPx and
CAT were defined as the amount of enzyme causes the 1.0 nmol
NADPH oxidation and the amount of enzyme causes the
formation of 1.0 nmol formaldehyde per min/mg of total cellular
protein per assay respectively. SOD activity was calculated using
the SOD standard curve and expressed as U/mg of total cellular
protein.
Image and data analysis on cell cultures
Analysis and photography of fluorescent immunostaind cells
were carried out using an inverted Leica SP5 confocal microscope.
Results are shown as the mean 6 standard error of the mean
(SEM) of data extracted from three experiments unless stated
otherwise. Statistical differences were determined with a one-way
analysis of variance (ANOVA) followed by Dunnett’s test. P values
#0.01 will be considered significant.
Results
SurR9-C84A protects against H2O2 induced cytotoxicity
Preliminary, to find the effect of SurR9-C84A therapy the
differentiated SK-N-SH cells were treated with different concen-
trations of SurR9-C84A for 24 hr. A dose-dependent increase in
the viability of differentiated SK-N-SH cells was found (Fig. 1A).
To evaluate whether H2O2 affects the viability of differentiated
SK-N-SH cells, these cells were treated with different concentra-
tions of H2O2 (0, 10, 30, 100, 200 and 500 mM) for 24 hr. The
H2O2 treatment led to a dose-dependent decrease in the viability
of differentiated SK-N-SH cells (Fig. 1B).
Furthermore, to determine the protective effects of SurR9-
C84A, differentiated SK-N-SH cells were pre-treated with 75 mg
of SurR9-C84A, followed by treatment with 300 mMH 2O2 for
24 hr. The H2O2-induced loss of cell viability was significantly
attenuated by SurR9-C84A treatment (P,0.05) (Fig. 1C).
To further investigate the protective effects of SurR9-C84A,
LDH release was evaluated as a second indicator of toxicity. There
was a considerable increase in LDH release following exposure to
300 mMH 2O2 (5063.4%, P,0.05) (Fig. 1d), indicating an
Figure 1. SurR9-C84A attenuate H2O2 induced cell death. SK-N-SH cells were differentiated using 20 mM retinoic acid for 10 days and
ddifferentiated media were replaced with growth media. (A) Differentiated cells were treated with different concentration of SurR9-C84A for 24 hr
and cell viability was determined using MTT assay. (B) Differentiated SK-N-SH cells were treated with different concentration of H2O2 and cell viability
was determined using MTT assay. (C, D) Differentiated SK-N-SH cells were pre-treated with 75 mg/ml of SurR9-C84A or ascorbic acid for 24 hr followed
by treatment with 300 mMo fH 2O2 for 24 hr. The cell viability and toxicity were determined using (C) MTT and (D) LDH assays, respectively. Data are
representative of at least three independent experiments and expressed as mean6SEM; *P,0.05, **P,0.01.
doi:10.1371/journal.pone.0015865.g001
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pre-treatment with SurR9-C84A for a period of 24 hr significantly
reduced LDH release by (3064.63%, P,0.05). We also compared
the protective effect of SurR9-C84A with ascorbic acid in the same
experimental condition and found that pre-treatment with
ascorbic acid reduces the LDH release by (2863.42%, P,0.05).
SurR9-C84A pre-treatment attenuates cell death
Considering the high level of apoptotic neuronal loss during
PD, we studied the protective effects of SurR9-C84A against
H2O2-induced apoptosis using TUNEL and PI staining assays.
Our results showed that oxidative stress increases the population
of apoptotic cells to (5861.69%, P,0.01) compared to the
Figure 2. SurR9-C84A prevents H2O2 induced apoptosis and necrosis in differentiated SK-N-SH cells. SK-N-SH cells were differentiated
with 20 mM RA for 10 days. Differentiation media were replaced with growth media and cells were treated with (A–C) 300 mMH 2O2, (D–E) Control, (G–I)
75 mg/ml SurR9-C84A +300 mMH 2O2 and (J–L) 75 mg/ml ascorbic acid +300 mMH 2O2 for 24 hr. (M) graph shows the percentage of apoptotic and
necrotic cells. Neuronal cells were stained with TUNEL/Propidium iodine double staining and analysed using confocal microscopy as described in
materials and methods. The values are presented as the percentage of total number of cells and shown as mean6SEM of three independent
experiments. At least 100 cells were counted in each treatment. Bar is 10 mm.
doi:10.1371/journal.pone.0015865.g002
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reduced the percentage of apoptotic cells by (40612%,
P,0.01) compared to the cells treated with H2O2 alone whereas
pre-treatment with ascorbic acid improved the population of
apoptotic cells by (18612%, P,0.05). These results revealed
that SurR9-C84A protects differentiated SK-N-SH cells from
H2O2-induced DNA fragmentation and cell death, highlighting
its anti-apoptotic effect on differentiated SK-N-SH cells (Fig. 2).
Figure 3. SurR9-C84A prevents mitochondrial depolarization. SK-N-SH cells were differentiated with 20 mM retinoic acid for 10 days.
Differentiated media were replaced with growth media and cells were pre-treated with 75 mg/ml of SurR9-C84A or ascorbic acid for 24 hr followed by
treatment with 300 mMo fH 2O2 for 24 hr. At the end of incubation mitochondrial membrane depolarization was qualified and quantified with
MitoLight Mitochondrial kit using both techniques of (A) confocal microscopy and (B) spectrofluorometery (see material and method). Green
fluorescence (detection of monomers) indicates the presence of depolarized mitochondria (apoptotic cells). Red fluorescence (J-aggregates) indicates
the functional and polarized mitochondria. Values are presented as a percentage of increase in mitochondrial depolarization. Data are representative
of at least three independent experiments and expressed as mean6SEM; *P,0.05, **P,0.01.
doi:10.1371/journal.pone.0015865.g003
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the mitochondrial membrane potential
To clarify the mechanism underlying the anti-apoptotic effects
of SurR9-C84A, we evaluated any reduction in the mitochondrial
transmembrane potential as an early apoptotic event, and any
increased in cleavage of caspases 9 and 3 and expression of cyclin
D1, all markers of neuronal cell death.
We evaluated the mitochondrial membrane potential to
determine whether H2O2-induced apoptosis and the protective
effects of SurR9-C84A occur through the mitochondrial pathway.
Exposing differentiated SK-N-SH cells to H2O2 decreased the
mitochondrial membrane potential to 54.1364.32% (p,0.01)
(Fig. 3D–F, M). Pre-treatment with SurR9-C84A for 24 hr,
however, increased the mitochondrial membrane potential to
6566.29% (p,0.05) (Fig. 3G–I, M) compared to the cells treated
with H2O2 alone whereas pre-treatment with ascorbic acid
improved the mitochondrial membrane potential to 64.668.9%
(p,0.05) (Fig. 3J–L, M). These results showed that the pre-
treatment of differentiated SK-N-SH cells with SurR9-C84A
decreases the H2O2-induced mitochondrial membrane potential,
which was comparable to results obtained by ascorbic acid.
In addition, using the same experimental conditions, pre-
treatment with SurR9-C84A showed an inhibitory effect on the
activation of caspases 9 and 3. As shown in Fig. 4, exposure of cells
to the H2O2 did not affect the expression of cyclin D1 while
significantly increased cleavage of caspase 9 (660.30 fold; P,0.01)
and caspase 3 (760.20 fold; P,0.01). Furthermore, pre-treatment
with ascorbic acid reduced the activation of caspase 9 (51613.6%;
P,0.01) and caspase 3 (6068.6%; P,0.01) while no significant
difference was observed in the expression of cyclin D1.
More importantly, pre-treatment with SurR9-C84A showed a
significant inhibitory effect on the cleavage of caspase 9
(55%65.36; P,0.01) and caspase 3 (35%60.89; P,0.01) and
also on the expression of cyclin D1 (52%66.4; P,0.05).
With regard to the late stage of apoptosis, we evaluated the
inhibitory effect of SurR9-C84A on DNA fragmentation. A 24 hr
treatment with 300 mMH 2O2 increased the DNA fragmentation to
88.367.26% (P,0.05). Interestingly, pre-treatment with SurR9-
C84A for 24 hr reduced the DNA fragmentation to 34.565.4%
(p,0.01). Alternatively, pre-treatment with ascorbic acid reduced
the DNA fragmentation to 56.766.32 (P,0.01), which was 25%
less effective compared to the SurR9-C84A pre-treatment.
SurR9-C84A improves antioxidant activity of
differentiated SK-N-SH cells
To determine whether the observed neuroprotective effect of
SurR9-C84A could be translated to antioxidant activity, we
studied the ability of SurR9-C84A to induce GSH related
enzymes. As shown in Table 1, pre-treatment with 75 mg/ml of
SurR9-C84A significantly increased the activity of GSHR
(2.3760.06 fold, P,0.05), GST (1.4661.11 fold, P,0.05) and
GSHPx (1.2560.31 fold, P,0.05) compared to the control level.
We next considered the activities of other enzymes, including
SOD and CAT, which are involved in the specific detoxification of
H2O2. Notably, a significant increase in the activity of SOD was
observed following treatment with SurR9-C84A (1.5360.005 fold,
P,0.05).
In order to ascertain whether the increase in antioxidant activity
following SurR9-C84A treatment could be translated into
cytoprotective effects, we studied the protective effects of SurR9-
C84A pre-treatment against H2O2 toxicity. During the oxidative
stress condition the level of enzyme activity reduced in GSHR
(3361.56%, P,0.01), GSHT (29.4864.69%, P,0.05) and
GSHPx (40.6464.69%, P,0.01) and the reduction was replen-
ished corresponding to SurR9-C84A therapy. Pre-treatment of
differentiated SK-N-SH cells with 70 mg/ml SurR9-C84A for
24 hr had a significant protective effect against H2O2 toxicity, and
this result was considerably correlated with the increased activity
of GSHR (2.860.03 fold, P,0.01) and GSHT (1.1960.5 fold,
P,0.05) compared to the H2O2 treated cells.
Discussion
Exit from the cell cycle is the most important feature of
differentiated neurons that makes them different from the other
Figure 4. SurR9-C84A pre-treatment prevents expression of
neuronal cell death markers such as cyclin D1, caspase 9 and 3.
SK-N-SH cells were differentiated for 10 days with 20 mM RA. After the
differentiation period the media was replaced with cell growth media
and cells were pre-treated with 75 mg/ml SurR9-C84A or 75 mg/ml
ascorbic acid for 24 hr followed by treatment with 300 mMH 2O2 for
24 hr. (A) cell lysate was prepared and western blot analysis was
performed to study the expression of cyclin D1. The loading of each
lane was normalised to the level of b-Actin. (B) ELISA assay was
performed for cleavage of caspase9 and 3 as described in materials and
methods. SurR9-C84A protects the nucleus damage. Cells were pre-
treated with 75 mg/ml SurR9-C84A or ascorbic acid for 24 hr followed
by treatment with 300 mMH 2O2 for 24 hr and stained with PI. Arrows
show the damage nuclei. (C) Percentage of cells with abnormal nuclei.
doi:10.1371/journal.pone.0015865.g004
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molecules and regulators of the cell cycle that are active in the
other cells seem to be inactivate in routine neuronal biochemistry.
Failure to exit the cell cycle and activation of a molecular cell cycle
program by DArgic neurons has been reported in both PD and
AD. For example, cyclin D1 expression has been observed in
DArgic neurons in the postmortem substantia nigra pars compacta
(SNc) of PD patients [22,23,24,25,26]. In addition, different genes
underlying the familial forms of PD have been linked to cancer
and cell cycle regulation [23]. Therefore, targeting cell cycle
markers seems to be a promising approach to protect the SNc
from oxidative damage [21].
We report here for the first time a neuroprotective effect of a
cell-permeable form of a survivin mutant (SurR9-C84A) against
H2O2-induced neurotoxicity. The cysteine at position 84 in the
zinc-coordination site of SurR9-C84A was replaced with alanine,
and the amino-terminus was fused to a nine-arginine (R9) peptide
to render it cell permeable [19]. Using the R9 peptide has
advantages over other carriers due to its greater cellular uptake
[27]. It is also superior to other viral systems because it is less toxic
and does not induce a significant immune response [28], an
important point for future in vivo studies.
SurR9-C84A was employed to investigate the survival mecha-
nisms in differentiated DArgic such as neuroblastoma SK-N-SH
cells following the H2O2-induced apoptosis, which has not been
studied previously.
The SurR9-C84A protein has been shown to bind to
polymerised microtubules and to localise to the microtubule
organising centre of interphase cells in a manner indistinguishable
from that of wild-type survivin [29]. We previously reported that
SurR9-C84A has a protective effect against post differentiation
RA-induced cell death [20]; however, no study has been done on
neuroprotective therapy with this mutant against oxidative
injuries. Hydrogen peroxide is a central molecule involved in the
neuronal loss observed in both AD and PD [30]. In this regard,
our results show that pre-treatment with SurR9-C84A can
increase the viability of neuronal cells and inhibit cell death due
to H2O2-induced damage. Based on previous results, deregulation
of cell cycle markers can elicit apoptosis in post mitotic neurons,
which is one of the primary mechanisms leading to cell death in
degenerating neurons, including DArgic neurons [23]. We also
found an increase in cyclin D1 expression following H2O2
treatment; however, pre-treatment with SurR9-C84A blocked this
increase.
Based on previous in vitro and clinical studies beta amyloid (Ab),
dopamine and 6-OHDA can lead to cell death by direct H2O2-
induced mitochondrial transmembrane depolarisation and the
subsequent activation of caspases 9 and 3 [30]. In the present
study, treatment of differentiated SK-N-SH cells with H2O2 also
resulted in a significant increase in the population of apoptotic and
necrotic cells, mitochondrial membrane depolarisation and
activation of caspases 9 and 3. More importantly, we demonstrat-
ed that pre-treatment of differentiated SK-N-SH with SurR9-
C84A induces marked resistance to neuronal death in terms of the
apoptosis and necrosis elicited by H2O2. In particular, we showed
for the first time that the neuroprotective effects of SurR9-C84A
can be attributed to its ability to prevent mitochondrial
depolarisation and the activation of apoptotic signalling mediated
by caspases 9 and 3, which are responsible for DNA damage.
Several different strategies have been proposed to limit oxidative
stress, including ascorbic acid therapy. As a control, we compared
the effectiveness of our treatment to ascorbic acid and found a
superior protective effect of SurR9-C84A against apoptosis and
necrosis, mitochondrial membrane depolarisation and activation
of caspases 9 and 3.
The involvement of oxidative stress in Parkinson’s and
Alzheimer’s disease and amyotrophic lateral sclerosis has been
extensively suggested in the literature. For example, GST has
been reported to be involved in the survival of DArgic neurons
in PD [31,32], whereas CAT and SOD have been reported to
have important roles in cellular defence against oxidative stress
as decreases in their activity have been observed in parkinso-
nian brains. To evaluate the effects of our treatment on GST,
GSHR, GSHPx, CAT and SOD, we studied the activation of
these enzymes following SurR9-C84A treatment and found an
increase in GST, GSHR and CAT activity, but not SOD
activity.
Given that this is the first report of a protective effect of SurR9-
C84A following an oxidative stress injury, further work should be
done to study the effects of SurR9-C84A on in vivo models of
degenerative diseases. In summary, we report for the first time, a
recombinant, cell-permeable form of the survivin mutant protein
(SurR9-C84A) efficiently enters neuronal cells, protects differen-
tiated SK-N-SH cells from the activation of apoptosis induced by
H2O2, decreases the expression of cell cycle markers, and increases
antioxidant activity. Emerging nano-delivery systems could be
used to bypass the blood brain barrier, facilitating drug delivery to
the damaged brain [33].
Author Contributions
Performed the experiments: SB. Analyzed the data: SB. Contributed
reagents/materials/analysis tools: SB RKK JRK. Wrote the paper: SB.
References
1. Barone P (2010) Neurotransmission in Parkinson’s disease: beyond dopamine.
European Journal of Neurology 17: 364–376.
2. Jenner P (2003) Oxidative stress in Parkinson’s disease. Annals of Neurology 53:
S26–S36.
Table 1. Effects of SurR9-C84A treatment on SOD, CAT, GST, GSHPx and GSHR activity on differentiated SK-N-SH cells.
Control SurR9-C84A H2O2 SurR9-C84A +H2O2
SOD (U/mg) 0.03260.005 0.04960.002* 0.6160.03 0.5260.02
CAT(nmol/min/mg) 0.8460.05 1.1660.04 0.2160.03 0.9160.05**
GST (nmol/min/mg) 13.0960.01 19.1261.1* 9.9460.2 11.8960.3*
GSHPx (nmol/min/mg) 1.0660.02 1.3260.11* 0.5860.07 0.6960.03
GSHR (nmol/min/mg) 2.5860.05 6.1260.01** 1.5260.02 4.3560.01**
doi:10.1371/journal.pone.0015865.t001
Survivin Mutant Protects Against Oxidative Stress
PLoS ONE | www.plosone.org 7 January 2011 | Volume 6 | Issue 1 | e158653. Kanwar JR, Kanwar RK, Burrow H, Baratchi S (2009) Recent Advances on the
Roles of NO in Cancer and Chronic Inflammatory Disorders. Current
Medicinal Chemistry 16: 2373–2394.
4. Lotharius J, Brundin P (2002) Pathogenesis of Parkinson’s disease: Dopamine,
vesicles and alpha-synuclein. Nature Reviews Neuroscience 3: 932–942.
5. Graham DG (1978) Oxidative pathways for catecholamines in the genesis of
neuromelanin and cytotoxic quinones. Molecular Pharmacology 14: 633–643.
6. Mattson MP, Liu D (2002) Energetics and oxidative stress in synaptic plasticity
and neurodegenerative disorders. Neuromolecular Medicine 2: 215–231.
7. Xu DG, Crocker SJ, Doucet JP, StJean M, Tamai K, et al. (1997) Elevation of
neuronal expression of NAIP reduces ischemic damage in the rat hippocampus.
Nature Medicine 3: 997–1004.
8. Perrelet D, Ferri A, MacKenzie AE, Smith GM, Korneluk RG, et al. (2000) IAP
family proteins delay motoneuron cell death in vivo. European Journal of
Neuroscience 12: 2059–2067.
9. Donnini S, Solito R, Monti M, Balduini W, Carloni S, et al. (2009) Prevention of
ischemic brain injury by treatment with the membrane penetrating apoptosis
inhibitor, TAT-BH4. Cell Cycle 8: 1271–1278.
10. Kanwar JR, Shen WP, Kanwar RK, Berg RW, Krissansen GW (2001) Effects of
survivin antagonists on growth of established tumors and B7-1 immunogene
therapy. Journal of the National Cancer Institute 93: 1541–1552.
11. Kanwar JR, Shen WP, Kanwar RK, Sun XY, Berg RW, et al. (2004) Survivin
antagonists and antisense HIF-1 alpha stimulate the generation of tumor-specific
CTLs: May be beneficial for the treatment of large lymphomas. Cancer Gene
Therapy 11: 853.
12. Kanwar RK, Cheung CHA, Chang JY, Kanwar JR (2010) Recent Advances in
Anti-Survivin Treatments for Cancer. Current Medicinal Chemistry 17:
1509–1515.
13. Makrantoni V, Stark MJR (2009) Efficient Chromosome Biorientation and the
Tension Checkpoint in Saccharomyces cerevisiae both Require Bir1. Molecular
and Cellular Biology 29: 4552–4562.
14. Marusawa H, Matsuzawa S, Welsh K, Zou H, Armstrong R, et al. (2003)
HBXIP functions as a cofactor of survivin in apoptosis suppression. Embo
Journal 22: 2729–2740.
15. Dohi T, Xia F, Altieri DC (2007) Compartmentalized phosphorylation of IAP
by protein kinase A regulates cytoprotection. Molecular Cell 27: 17–28.
16. Baratchi S, Kanwar RK, Kanwar JR (2010) Survivin: A target from brain cancer
to neurodegenerative disease. Crit Rev Biochem Mol Biol 45: 535–554.
17. Baratchi S, Kanwar RK, Kanwar JR (2010) Novel Survivin Mutant Protects
Differentiated SK-N-SH Human Neuroblastoma Cells from Activated T-cell
Neurotoxicity. Journal of neuroimmunology [Epub ahead of print].
18. Chang PA, Chen R, Wu YJ (2005) Reduction of neuropathy target esterase does
not affect neuronal differentiation, but moderate expression induces neuronal
differentiation in human neuroblastoma (SK-N-SH) cell line. Molecular Brain
Research 141: 30–38.
19. Cheung CHA, Kanwar J, Krissansen GW (2006) A cell-permeable dominant-
negative Survivin protein as a tool to understand how Survivin maintains
tumour cell survival. Ejc Supplements 4: 488.
20. Baratchi S, Kanwar RK, Chun HAC, Kanwar JR (2010) Proliferective and
protective effects of SurR9-C84A on differentiated neuronal cells. Journal of
NeuroImmunology 227: 120–132.
21. Herrup K, Yang Y (2007) Cell cycle regulation in the postmitotic neuron:
oxymoron or new biology? Nature Reviews Neuroscience 8: 368–378.
22. Burns KA, Ayoub AE, Breunig JJ, Adhami F, Weng WL, et al. (2007) Nestin-
CreER mice reveal DNA synthesis by nonapoptotic neurons following cerebral
ischemia-hypoxia. Cerebral Cortex 17: 2585–2592.
23. West AB, Dawson VL, Dawson TM (2005) To die or grow: Parkinson’s disease
and cancer. Trends in Neurosciences 28: 348–352.
24. Jordan-Sciutto KL, Wang GJ, Murphey-Corb M, Wiley CA (2002) Cell cycle
proteins exhibit altered expression patterns in lentiviral-associated encephalitis.
Journal of Neuroscience 22: 2185–2195.
25. Hoeglinger GU, Breunig JJ, Depboylu C, Rouaux C, Michel PP, et al. (2007)
The pRb/E2F cell-cycle pathway mediates cell death in Parkinson’s disease.
Proceedings of the National Academy of Sciences of the United States of
America 104: 3585–3590.
26. Yang Y, Herrup K (2005) Loss of neuronal cell cycle control in ataxia-
telangiectasia: A unified disease mechanism. Journal of Neuroscience 25:
2522–2529.
27. Mitchell DJ, Kim DT, Steinman L, Fathman CG, Rothbard JB (2000)
Polyarginine enters cells more efficiently than other polycationic homopolymers.
Journal of Peptide Research 56: 318–325.
28. Morris MC, Chaloin L, Heitz F, Divita G (2000) Translocating peptides and
proteins and their use for gene delivery. Current Opinion in Biotechnology 11:
461–466.
29. Li FZ, Ambrosini G, Chu EY, Plescia J, Tognin S, et al. (1998) Control of
apoptosis and mitotic spindle checkpoint by survivin. Nature 396: 580–584.
30. del Rio MJ, Velez-Pardo C (2004) The hydrogen peroxide and its importance in
Alzheimer’s and Parkinson’s disease. Current Medicinal Chemistry - Central
Nervous System Agents 4: 279–285.
31. Johannsen P, Velander G, Mai J, Thorling EB, Dupont E (1991) Glutathione
peroxidase in early and advanced Parkinson’s disease. Journal of Neurology
Neurosurgery and Psychiatry 54: 679–682.
32. Damier P, Hirsch EC, Zhang P, Agid Y, Javoyagid F (1993) Glutathione-
peroxidase, glial-cells and parkinsons-disease. Neuroscience 52: 1–6.
33. Baratchi S, Kanwar RK, Khoshmanesh K, Vasu P, Ashok C, et al. (2009)
Promises of Nanotechnology for Drug Delivery to Brain in Neurodegenerative
Diseases. Current Nanoscience 5: 15–25.
Survivin Mutant Protects Against Oxidative Stress
PLoS ONE | www.plosone.org 8 January 2011 | Volume 6 | Issue 1 | e15865